- Home
- CLNN
CLNN
Clene Inc.
as 11-20-2024 4:00pm EST
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 43.0M | IPO Year: | N/A |
| Target Price: | $59.25 | AVG Volume (30 days): | 56.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.82 - $12.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | $421,000 | Revenue Growth: | -41.36% |
| Revenue Growth (this year): | -39.86% | Revenue Growth (next year): | 1058.37% |
Latest Clene Inc. News
CLNN Breaking Stock News: Dive into CLNN Ticker-Specific Updates for Smart Investing
TipRanks
6 days ago
Clene price target lowered to $83 from $86 at Canaccord
GlobeNewswire
8 days ago
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights
NewMediaWire
a month ago
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership
NewMediaWire
a month ago
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences
NewMediaWire
a month ago
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements
NewMediaWire
a month ago
IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
GlobeNewswire
a month ago
Clene to Present at Upcoming October Conferences
Simply Wall St.
2 months ago
Independent Chairman of the Board of Clene David Matlin Buys 26% More Shares
Compare CLNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLNN Clene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.